Bisantrene is a newer anthracycline derivative currently being investigated in phase 2 trials. One presumed advantage of bisantrene is that it is purportedly free of cardiotoxic effects. However, bisantrene apparently precipitated congestive heart failure after a single intravenous infusion in a young boy, prompting our study of a second child who remained asymptomatic but had transient declines in cardiac function after receiving bisantrene. Since bisantrene may acutely depress myocardial contractile function, further investigation is necessary.
|Original language||English (US)|
|Number of pages||2|
|Journal||Southern Medical Journal|
|State||Published - 1985|
ASJC Scopus subject areas